Multicenter phase II trial of S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable colorectal cancer

被引：0
|
作者：
Shin, S.
Park, Y.
Kim, T.
Oh, D.
Shim, B.
Lee, K.
Lee, M.
Kim, Y.
Kim, Y.
Ahn, J.
机构：
[1] Yonsei Canc Ctr, Seoul, South Korea
[2] Samsung Med Ctr, Seoul, South Korea
[3] Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[5] St Vincents Hosp, Suwon, South Korea
[6] Yeungnam Univ, Coll Med, Taegu, South Korea
[7] St Marys Hosp, Seoul, South Korea
[8] Korea Univ, Coll Med, Seoul 136705, South Korea
[9] Natl Hlth Insurance Corp Ilsan Hospit, Ilsan, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.15057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15057
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
    J-L Lee
    Y-K Kang
    H J Kang
    K-H Lee
    D Y Zang
    B-Y Ryoo
    J G Kim
    S R Park
    W K Kang
    D B Shin
    M-H Ryu
    H M Chang
    T-W Kim
    J H Baek
    Y J Min
    [J]. British Journal of Cancer, 2008, 99 : 584 - 590
  • [2] A randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in unresectable or recurrent breast cancer patients
    Yamamoto, D.
    Iwase, S.
    Odagiri, H.
    Kuroda, Y.
    Akazawa, K.
    Kitamura, K.
    Kawaguchi, T.
    Yamamoto, C.
    Nagumo, Y.
    Sakata, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
    Kang, Y.
    Lee, J.
    Min, Y.
    Lee, K.
    Zang, D.
    Ryoo, B.
    Kim, J.
    Park, S.
    Kang, W.
    Shin, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
    Kang, Y.
    Lee, J.
    Min, Y.
    Lee, K.
    Zang, D.
    Ryoo, B.
    Kim, J.
    Park, S.
    Kang, W.
    Shin, D.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII25 - VII25
  • [5] Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
    Yoo, Changhoon
    Han, Boram
    Kim, Hyeong Su
    Kim, Kyu-pyo
    Kim, Deokhoon
    Jeong, Jae Ho
    Lee, Jae-Lyun
    Kim, Tae Won
    Kim, Jung Han
    Choi, Dae Ro
    Ha, Hong Il
    Seo, Jinwon
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    Zang, Dae Young
    [J]. CANCER RESEARCH AND TREATMENT, 2018, 50 (04): : 1324 - 1330
  • [6] Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
    Takahari, D.
    Takiuchi, H.
    Muro, K.
    Tsuji, A.
    Hamamoto, Y.
    Yoshino, T.
    Yoshida, K.
    Shirao, K.
    Miyata, Y.
    Ohtsu, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S428 - S429
  • [7] A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
    Lee, J-L
    Kang, Y-K
    Kang, H. J.
    Lee, K-H
    Zang, D. Y.
    Ryoo, B-Y
    Kim, J. G.
    Park, S. R.
    Kang, W. K.
    Shin, D. B.
    Ryu, M-H
    Chang, H. M.
    Kim, T-W
    Baek, J. H.
    Min, Y. J.
    [J]. BRITISH JOURNAL OF CANCER, 2008, 99 (04) : 584 - 590
  • [8] A phase II study of S-1 and oxaliplatin as first-line therapy for patients with recurrent or metastatic gastric cancer
    Kim, H.
    Lee, G.
    Kim, H.
    Lee, O.
    Hwang, I.
    Kang, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] A PHASE II STUDY OF S-1 AND OXALIPLATIN AS FIRST-LINE THERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC GASTRIC CANCER
    Kim, H. G.
    Kang, M.
    Kim, S.
    Lee, S. I.
    Lee, G.
    Kang, J. H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 182 - 182
  • [10] Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
    Assenat, Eric
    Desseigne, Francoise
    Thezenas, Simon
    Viret, Frederic
    Mineur, Laurent
    Kramar, Andrew
    Samalin, Emmanuelle
    Portales, Fabienne
    Bibeau, Frederic
    Crapez-Lopez, Evelyne
    Bleuse, Jean Pierre
    Ychou, Marc
    [J]. ONCOLOGIST, 2011, 16 (11): : 1557 - 1564
12345